The Wall Street Journal has published a feature on Shanghai's emergence as a destination for cancer patients from the United States and other developed countries. Central to it is Shanghai SinoUnited Hospital, its CAR-T programme, and one patient whose story makes the argument better than any statistic: a 25-year-old from New Zealand who was quoted US$600,000 in Melbourne, was treated in Shanghai for less than half that, and learned in August that his lymphoma had completely responded.
The paper's framing is worth stating plainly, because it is the part Chinese hospitals usually get wrong when they retell such coverage: CAR-T was invented in the United States. What China has done is industrialise it — and in the number of approved products, in access, and in cost efficiency, that industrialisation now shows. SinoUnited was cited as one of the institutions that demonstrates the trend.
1. Non-Hodgkin lymphoma, and three lines of treatment that did not hold
Michael Walters was diagnosed with non-Hodgkin lymphoma not long after finishing university. He was treated in Auckland through several rounds of chemotherapy, radiotherapy and immunotherapy. The disease did not come under control. At that point his doctors raised CAR-T: collect the patient's own immune cells, engineer them in a laboratory, and return them to the body to attack the cancer.
“I value my life more now,” Walters told the paper. “Ten or fifteen years ago, I wouldn't have had this option.”
2. Why the price gap is not the whole story
The numbers in the feature are blunt. China has approved nine CAR-T products — more than any other country — and has offered CAR-T to overseas patients since 2021. In June 2026 it approved the world's first CAR-T therapy for a solid tumour, aimed at cancers of the stomach and upper small intestine.
The WSJ's explanation for that gap is not cheap labour but scale: China has done with CAR-T something like what it did in other industries, pushing cost down and throughput up by industrialising the process. Part of it is also physical. CAR-T has to be manufactured for one patient at a time, and Chinese laboratories close to Shanghai can complete the run in days — a difference that matters to someone whose cancer is aggressive and whose calendar is not negotiable.
3. “Not only because of the cost”
Dr. Kathy Shi, founder and CEO of SinoUnited Health and president of Shanghai SinoUnited Hospital, told the paper that as word has spread, the hospital has received patients who were previously treated at MD Anderson, Mayo Clinic and Johns Hopkins, with enquiries rising from the United States, Canada, Europe and Southeast Asia.
Her argument, which the reporting takes up, is that cost is necessary but not sufficient. International patients choose China for a model of care as much as for a price: a private international hospital that can convene several specialties around one patient and carry them through the whole process, in English. Dr. Shi completed postdoctoral research at Emory University.
4. What CAR-T actually asks of a hospital
The feature is unusually clear about the operational bill that comes with the therapy. CAR-T can require intensive care, and it can require cardiology and neurology to be available the same night — the complications are not confined to the tumour. A hospital that can manufacture cells but cannot staff that response is not offering CAR-T; it is offering the infusion.
Since launching the programme in 2023, Shanghai SinoUnited has treated roughly 30 international patients from 12 countries, and most are currently cancer-free. The hospital runs a dedicated CAR-T Cell Therapy International Consultation Centre for eligibility review, cell collection, infusion, inpatient monitoring and follow-up with the patient's physician at home.
5. The video call that decided it
Walters has said that what made Shanghai feel possible was not the price list but the first conversation — a video call with Dr. Zhou Lili, director of the hospital's CAR-T Cell Therapy International Consultation Centre and of haematology. She completed postdoctoral research at the University of California, San Francisco, and has worked in haematological oncology for more than two decades.
“In New Zealand I felt I was doing more research than the doctors I was speaking to,” he said. “But she was extremely experienced, and it was such a relief to talk to someone who knew exactly what she was doing.”
That sentence is the one worth keeping. For a patient who has already been through three lines of treatment, the decisive variable is rarely a brochure. It is whether the person on the other end of the call has seen this before.
6. A birthday, and an ordinary list
On his 25th birthday, the hospital's staff brought Walters a cake. He plans to spend the next one at home in Auckland, and hopes the disease will still be in remission when he does.
“Right now, I'd give anything just to be healthy,” he said. “I want to worry about ordinary things like everyone else: university, work, a girlfriend, gossip.”
A note on this article. It is compiled from SinoUnited Health's account of The Wall Street Journal's feature, with some wording edited for length. A complete remission in one patient is a real outcome, not a promise of one: CAR-T is appropriate only for specific diagnoses and disease stages, requires specialist assessment, and carries serious risks including cytokine release syndrome and neurological toxicity. Nothing here is a substitute for that assessment.
About Dr. Zhou Lili
Dr. Zhou Lili is director of the CAR-T Cell Therapy International Consultation Centre and director of haematology at SinoUnited Health. She holds a doctorate in medicine and completed postdoctoral research at the University of California, San Francisco, and has worked in haematological oncology for 22 years.
Her clinical focus is haematological malignancy — multiple myeloma, lymphoma, and acute and chronic leukaemia — alongside the standardised management of benign blood disorders including anaemia, thrombocytopenia and coagulation disorders. She has extensive experience of CAR-T cell immunotherapy in myeloma, lymphoma and leukaemia, as well as solid-tumour cell therapy, targeted therapy and newer immunotherapies, with a large caseload of complex cases and their long-term management.
Dr. Zhou sits on the haematology committee of the Shanghai Medical Association and on committees of the Shanghai Pharmaceutical Industry Association, the Chinese Association of Rehabilitation Medicine and the Chinese Medical Association's haematology branch. She is a member of the American Society of Clinical Oncology. She has led projects funded by the UCSF myeloma translational medicine fund, the National Natural Science Foundation of China, the Shanghai Pujiang Talent Programme and the Chinese Medical Doctor Association, has taken part in international multicentre trials, and has published 16 first-author SCI papers.
About the CAR-T International Consultation Centre
A dedicated pathway for international patients: eligibility review, lymphocyte collection, coordination of cell manufacturing, infusion and structured inpatient monitoring, and follow-up shared with the referring physician at home. The centre is a member of the Pan-Yangtze River Delta CAR-T Full-Process Management Expert Alliance and of the Shanghai Ruijin Haematology Medical Alliance.
Related reading
SinoUnited Opens CAR-T International Consultation Centre — what the centre does, how eligibility is assessed, and how a two-stage visit is planned around cell manufacturing.
SinoUnited Completes Its First International CAR-T Patients — the earliest international cohort, and what treating them changed.